SCHEMBL6318009

SCHEMBL6318009

CC(C)(C)OC(=O)CN[C@H](Cc1cccc2ccccc12)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.57
CTSK P43235 1/20 0.57
MME P08473 2/20 0.48
ACE P12821 2/20 0.48
CPA1 P15085 1/20 0.48
ACE2 Q9BYF1 1/20 0.48
HRH4 Q9H3N8 1/20 0.46
CTNNB1 P35222 1/20 0.45
MMP9 P14780 2/20 0.45
MMP8 P22894 1/20 0.44
MMP14 P50281 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TACR1 P25103 1/20 0.43
CYP3A4 P08684 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 1/20 0.41
NR1D1 P20393 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27563011 1.00 CTSS (0.57) CTSSCTSKMMEACECPA1
SCHEMBL9665152 0.87 CTSS (0.56) CTSSCTSKMMEACECPA1
SCHEMBL3768796 0.84 KMT2A (0.51) CTSSCTSKMMEACECPA1
SCHEMBL613640 0.82 CTSS (0.76) CTSSCTSKMMEACECPA1
SCHEMBL29401990 0.82 CTSS (0.76) CTSSCTSKMMEACECPA1
SCHEMBL4122289 0.82 CTSS (0.76) CTSSCTSKMMEACECPA1
SCHEMBL4600435 0.82 CTSS (0.76) CTSSCTSKMMEACECPA1
SCHEMBL2476918 0.82 ACE (0.54) CTSSCTSKMMEACEACE2
SCHEMBL3026223 0.82 ACE (0.54) CTSSCTSKMMEACEACE2
SCHEMBL3268059 0.82 ACE (0.54) CTSSCTSKMMEACEACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 CTSS 2319/4885CTSK 1324/4885MME 712/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR CTSS 2636/4885CTSK 1778/4885MME 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.